Pharmaceuticals News and Research

RSS

Raptor Pharmaceuticals announces positive results for Convivia program

Raptor Pharmaceuticals Corp. has announced positive results in its Phase IIa study of oral 4-methylpyrazole ("4-MP") in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development stage of its Convivia program.

11 Nov 2008

Rivaroxaban shows promise in patients with acute coronary syndrome

Researchers reported on a study of a new oral anti-clotting agent - rivaroxaban - designed to identify doses that would be safe to test in subsequent Phase III efficacy and safety trials. The results of ATLAS ACS-TIMI 46 were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008.

11 Nov 2008

Exercise training safe in heart failure patients - offer clinical benefit

Exercise training is safe in heart failure patients, does not significantly reduce hospitalization or death, but is associated with several improved clinical outcomes, even in those already receiving optimal medical care, researchers reported at the American Heart Association's Scientific Sessions 2008. The Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) was presented as a late-breaking clinical trial.

11 Nov 2008

Interferon eliminates specific causes of some viruses in heart failure patients, improving clinical outcomes

Giving interferon to heart failure patients with evidence of a chronic viral infection safely eliminated two viruses from their systems and reduced levels of a third virus.

11 Nov 2008

National call for cancer trial system to be more responsive to community needs

Addressing the nation's continuing poor performance in cancer clinical trial participation, particularly among racial and ethnic minorities and low income groups, will require meaningful public involvement in the design and implementation of clinical trials, according to a landmark report released today.

11 Nov 2008

Santaris Pharma releases positive data on LNA-based survivin inhibitor

Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.

10 Nov 2008

Testosterone patches charge up older women's sex

According to research by an international team of scientists testosterone could recharge the sex lives of older women.

10 Nov 2008

VIA Pharmaceuticals announces results of phase 2 trials of VIA-2291 in cardiovascular disease

VIA Pharmaceuticals, Inc. has announced the results of two Phase 2 studies of its lead drug, VIA-2291.

10 Nov 2008

Initiative by world-recognized specialists in heart disease and diabetes to reduce residual vascular risk

Residual Risk Reduction Initiative (R3i) Calls for Action to Reduce the Lipid-Related Residual Vascular Risk Unaddressed by Current Standards of Care in Millions of Patients With Heart Disease and Diabetes.

10 Nov 2008

Xolair (Omalizumab) shows promise in treating allergic asthma inadequately controlled by inhaled corticosteroid

Data presented today at the American College of Allergy, Asthma & Immunology (ACAAI) show that Xolair (Omalizumab) for Subcutaneous Use significantly reduced asthma attacks in children aged six through 11 with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids.

10 Nov 2008

New hybrid technology for disease prevention

The earlier cancer is diagnosed, the better the chance of effecting a cure.

10 Nov 2008

Spherix starts patient recruitment in India for phase 3 diabetes trial

Spherix Incorporated reported that patient recruitment for its Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose, has begun in India. Expectations for India are to provide more than 300 patients spread across 35 sites for the pivotal Phase 3 trial.

8 Nov 2008

New silver coated anti-microbial barrier dressing receives Canadian approval

NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and inflammation, and the Advanced Wound Management division of Smith & Nephew plc announced today that Health Canada granted marketing approval for Acticoat Flex barrier dressing for wounds that require up to seven days of sustained antimicrobial activity.

8 Nov 2008

Researchers discover metabolic deficiency in pancreatic cancer

UC Davis Cancer Center researchers have discovered a metabolic deficiency in pancreatic cancer cells that can be used to slow the progress of the deadliest of all cancers.

7 Nov 2008

Testosterone effective treatment for low libido in postmenopausal women

An international study showed testosterone, when used with no other hormone therapy, is an effective treatment for low libido in postmenopausal women.

7 Nov 2008

Sunesis Pharmaceuticals presents data of Voreloxin in patients with acute myeloid leukemia and ovarian cancer

Sunesis Pharmaceuticals, Inc. presented data from three clinical trials of the company's lead drug candidate, voreloxin (formerly SNS-595), at the Chemotherapy Foundation Symposium held in New York on November 4-8.

7 Nov 2008

Nanoparticles dramatically improve effectiveness of antibacterial treatments

Scientists at the University of Liverpool have developed a new technology which can dramatically improve the effectiveness of antibacterial treatments.

7 Nov 2008

FDA seizes Heparin from Cincinnati manufacturer

As part of the U.S. Food and Drug Administration's ongoing efforts to ensure that heparin for patients remains safe, the government today seized 11 lots of heparin from Celsus Laboratories Inc. in Cincinnati, Ohio.

7 Nov 2008

A new review of breast cancer prevention strategies in the U.S.

A new review outlines potential pharmaceutical, dietary, surgical, and other approaches to reducing the risk of breast cancer among women in the United States, and examines the evidence for specific recommendations.

6 Nov 2008

Needle-free injection device approved in Europe and Australia

Antares Pharma, Inc. today announced that its license partner, Ferring Pharmaceuticals has received additional regulatory approvals in Europe and Australia for use of Antares' needle-free injection devices with its human growth hormone (hGH), Zomacton.

6 Nov 2008